MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Importation Rules
20 questions · exam conditions
0:00
Importation RulesQuestion 1 of 20

A U.S. pharmacy purchases drug products from a foreign supplier that is FDA-registered as a drug establishment but not on the FDA's Import Alert list. Under DSCSA and FDCA importation requirements, what must the pharmacy ensure?

Ensure DSCSA-compliant transaction documentation and traceability from FDA-registered manufacturer through authorized domestic intermediaries.
FDA registration of the foreign supplier is sufficient to authorize the purchase.
The pharmacy need only verify the foreign supplier's state pharmacy license.
No additional compliance steps are required if the supplier is FDA-registered and not on an Import Alert.
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Importation Rules

Practice Importation Rules in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Importation Rules, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A U.S. pharmacy purchases drug products from a foreign supplier that is FDA-registered as a drug establishment but not on the FDA's Import Alert list. Under DSCSA and FDCA importation requirements, what must the pharmacy ensure?

  1. Ensure DSCSA-compliant transaction documentation and traceability from FDA-registered manufacturer through authorized domestic intermediaries. (correct answer)
  2. FDA registration of the foreign supplier is sufficient to authorize the purchase.
  3. The pharmacy need only verify the foreign supplier's state pharmacy license.
  4. No additional compliance steps are required if the supplier is FDA-registered and not on an Import Alert.
Explanation: Pharmacies must ensure products have DSCSA-compliant supply chain documentation: transaction information and a transaction statement per the current enhanced tracing framework, along with a verifiable serialized product identifier. Products imported directly from foreign sources without entering the domestic supply chain typically cannot provide the required DSCSA traceability documentation. A correctly identifies this dual FDCA and DSCSA compliance issue. B is incorrect because FDA establishment registration, while important, does not satisfy DSCSA supply chain documentation requirements for the full domestic chain of custody. C is incorrect because state pharmacy license verification is not the applicable standard here. D is incorrect because additional compliance verification is required beyond just registration and Import Alert status.

Question 2

A U.S. nonprofit organization wants to donate foreign-manufactured pharmaceutical products to a disaster relief effort in the United States. The products are not FDA-approved. Which of the following best applies?

  1. Unapproved foreign drugs require FDA authorization before distribution, even for charitable purposes. (correct answer)
  2. Donated drugs are exempt from FDCA requirements because they are not sold for commercial gain.
  3. Donated drugs are exempt because they are for disaster relief.
  4. Donated drugs from nonprofit organizations are automatically approved for use.
Explanation: The FDCA applies to drug distribution regardless of whether it is commercial or charitable. Unapproved foreign drugs may not be distributed in the United States even for disaster relief without FDA authorization. A correctly identifies this obligation. B is incorrect because nonprofit or non-commercial status does not exempt drug distribution from FDCA requirements. C is incorrect because disaster relief purposes, while compelling, do not automatically override FDCA requirements. D is incorrect because nonprofit status does not constitute FDA approval.

Question 3

A pharmacist is asked by a patient whether she can legally purchase prescription medications from an online pharmacy based in another country and have them shipped to her U.S. address. Which of the following is the most accurate response?

  1. Yes, this is legal if the online pharmacy is licensed in its country of origin.
  2. Yes, this is legal if the patient has a valid U.S. prescription for the medication.
  3. Yes, this is legal as long as the pharmacy does not ship more than a 3-month supply.
  4. No, purchasing prescription drugs from foreign online pharmacies for U.S. delivery is illegal under federal law. (correct answer)
Explanation: Purchasing from a foreign online pharmacy and importing to the U.S. is technically illegal under the FDCA. The FDA's enforcement discretion is not a legal authorization. Patients should understand the legal risk, safety concerns about product authenticity, and quality issues. D correctly describes this analysis. A is incorrect because foreign pharmacy licensure does not satisfy U.S. importation law. B is incorrect because a valid U.S. prescription addresses prescribing authority but not the import prohibition. C is incorrect because no FDA-authorized quantity exemption exists for this type of purchase.

Question 4

A Section 503B outsourcing facility wants to import a bulk active pharmaceutical ingredient (API) from a foreign manufacturer for use in compounding. Under FDA regulations, what must the foreign manufacturer have in order for the API to be lawfully imported?

  1. The foreign manufacturer need only be licensed in its home country.
  2. The foreign manufacturer must provide a Certificate of Analysis but no FDA registration is required.
  3. The foreign manufacturer must be registered with the FDA as a drug establishment for the API to be imported lawfully. (correct answer)
  4. No FDA involvement is required for API imports used in compounding because APIs are raw materials, not finished drugs.
Explanation: Foreign API manufacturers must be FDA-registered, and their APIs must meet applicable standards. The 503B facility must obtain documentation of identity, purity, and quality. C correctly identifies these requirements. A is incorrect because home country licensure alone does not satisfy FDA importation requirements. B is incorrect because FDA registration of the facility is required in addition to the CoA. D is incorrect because APIs used in compounding are regulated under the FDCA and subject to FDA oversight.

Question 5

A U.S. hospital wants to use a drug approved in the European Union for a condition in which it believes the European drug performs better than the FDA-approved alternative. Under federal law, what is required?

  1. The hospital may import the EU drug directly if it signs a quality agreement with the EU manufacturer.
  2. The hospital may import the EU drug if a licensed physician prescribes it to specific patients.
  3. FDA authorization via IND or expanded access is required to use an EU-approved drug not approved by the FDA. (correct answer)
  4. The hospital may freely import the EU drug because hospitals are exempt from FDCA importation requirements.
Explanation: Using an FDA-unapproved drug in a U.S. hospital requires either an IND or individual patient expanded access authorization. Clinical belief in superiority does not authorize importation and use. C correctly identifies the required pathways. A is incorrect because a quality agreement with a manufacturer does not satisfy FDCA importation law. B is incorrect because physician prescription does not authorize use of an unapproved imported drug outside an approved IND or expanded access framework. D is incorrect because hospitals are not exempt from FDCA requirements.

Question 6

A pharmacist working at a U.S.-based specialty pharmacy receives a request to source a specialty biologic from a supplier outside the authorized U.S. distribution channel, even though the drug is FDA-approved domestically. Which of the following best analyzes the compliance concern?

  1. There is no compliance concern because the drug is FDA-approved.
  2. Sourcing outside authorized channels risks violating FDCA importation laws and DSCSA documentation requirements. (correct answer)
  3. The compliance concern is limited to verifying that the product is not on an FDA Import Alert.
  4. There is no compliance concern if the product is stored properly during transport.
Explanation: Sourcing an FDA-approved drug outside authorized U.S. distribution channels creates multiple compliance risks: FDCA importation violations, DSCSA chain-of-custody failures, and product integrity concerns. FDA approval covers the product through authorized channels, not through parallel imports. B correctly identifies these risks. A is incorrect because domestic FDA approval does not authorize parallel importation outside authorized channels. C is incorrect because Import Alert status is one of many DSCSA and FDCA compliance considerations. D is incorrect because storage quality is only one of multiple compliance dimensions; importation law and DSCSA apply independently.

Question 7

A drug is available in the United States only through a REMS program requiring patient enrollment. A patient wants to import the same drug from a foreign country where it is available without restrictions. Which of the following best applies?

  1. The patient may import the drug because REMS requirements apply only to domestic dispensing.
  2. The patient may import the drug because REMS programs cannot restrict personal importation.
  3. The patient may import the drug if a foreign physician prescribes it.
  4. Importing a REMS-restricted drug bypasses safety measures and is prohibited under the FDCA. (correct answer)
Explanation: Importing a foreign version of a REMS-restricted drug is doubly problematic: it violates FDCA importation law and bypasses REMS safety requirements specifically created to manage serious drug risks. D correctly identifies both dimensions. A is incorrect because FDCA importation law applies regardless of REMS status. B is incorrect because REMS safety obligations are compelling reasons to apply additional scrutiny to such importation. C is incorrect because a foreign physician's prescription does not resolve U.S. importation law or REMS requirements.

Question 8

A patient purchases a drug from an online Canadian pharmacy and has it shipped to the United States. The drug is FDA-approved in the U.S. but the imported product comes from Canadian-labeled inventory. Which of the following best analyzes the compliance concern?

  1. There is no compliance concern because the drug is FDA-approved in the U.S.
  2. Importing Canadian-labeled drugs into the U.S. is illegal, despite FDA approval of the molecule. (correct answer)
  3. There is no compliance concern because the Canadian pharmacy is licensed.
  4. There is no compliance concern because the same molecule is FDA-approved.
Explanation: U.S. approval of a drug applies to specific products manufactured and labeled to U.S. standards. A Canadian-labeled product, even containing the same active ingredient, is not an FDA-approved U.S. product. Its importation is technically illegal regardless of the domestic approval status of the active ingredient. B correctly identifies this analysis. A is incorrect because domestic approval applies to the U.S.-labeled product, not to foreign-labeled versions. C is incorrect because Canadian pharmacy licensure does not resolve U.S. importation law. D is incorrect because molecule equivalence does not satisfy the FDA approval framework for specific drug products.

Question 9

A pharmacist receives a patient's request to help find a drug that is approved in Europe for a condition that has no FDA-approved treatment in the United States. The patient wants to know if there is a legal pathway. Which of the following best applies?

  1. The patient may simply import the European drug for personal use without any special authorization.
  2. There is no legal pathway; unapproved foreign drugs may never be used in the United States.
  3. The pharmacist should tell the patient to contact customs to negotiate an exemption.
  4. Expanded access allows investigational drugs for serious conditions without approved treatments, requiring physician FDA request. (correct answer)
Explanation: For patients needing unapproved foreign drugs for serious conditions with no approved alternatives, the FDA's expanded access (compassionate use) program under Section 561 is a legal pathway. D correctly identifies this option. A is incorrect because personal importation without authorization is technically illegal. B is incorrect because expanded access provides a legal pathway for unapproved drugs. C is incorrect because customs negotiations are not the appropriate pathway for accessing unapproved foreign drugs.

Question 10

A patient who travels to Mexico tells her pharmacist she purchases insulin there because it is cheaper. She asks for guidance on the legality. Which of the following best describes the applicable legal framework?

  1. It is fully legal because insulin is a humanitarian medication.
  2. It is fully legal in any quantity because traveling with personal medications is protected under federal law.
  3. Importing foreign insulin is technically illegal, but FDA may allow small personal-use quantities with enforcement discretion. (correct answer)
  4. It is legal in amounts not exceeding a 12-month supply.
Explanation: Carrying foreign-purchased prescription drugs across the border is technically importation prohibited by the FDCA. The FDA exercises enforcement discretion for small personal-use quantities but this is not a legal authorization. C correctly identifies both the prohibition and the enforcement discretion nuance. A is incorrect because humanitarian classification does not create a legal importation exemption. B is incorrect because personal use is not a federally protected exemption from FDCA importation prohibitions. D is incorrect because no 12-month quantity exemption exists under federal law.

Question 11

A shipment of foreign-manufactured drug products arrives at a U.S. port of entry and the FDA determines upon examination that the products appear to be misbranded. Which of the following describes the FDA's options?

  1. The FDA may only issue a warning letter; it cannot refuse admission of the products.
  2. The FDA may refuse admission and allow the importer to export or rectify the misbranding. (correct answer)
  3. The FDA must allow the products to enter but must notify the importer of the misbranding concern.
  4. The FDA must seize the products immediately without giving the importer any opportunity to respond.
Explanation: When FDA refuses admission to imported products determined to be misbranded, the importer typically has an opportunity to either export the products or bring them into compliance within a specified timeframe before the FDA proceeds with destruction. B correctly identifies these procedural options. A is incorrect because FDA may refuse admission; it is not limited to issuing warning letters. C is incorrect because FDA is not required to allow the products to enter the country; refusal of admission is an available and standard FDA option. D is incorrect because the importer is given an opportunity to respond, export, or recondition the product before destruction; immediate seizure without opportunity to respond is not the standard importation refusal procedure.

Question 12

What is the FDA's enforcement discretion policy regarding personal importation of prescription drugs from foreign countries?

  1. The FDA may allow personal importation of small drug quantities for personal use under enforcement discretion, not legal authorization. (correct answer)
  2. The FDA has formally authorized individual personal importation of prescription drugs from Canada in quantities up to a 90-day supply.
  3. The FDA has no enforcement authority over personal importation because personal use is exempt from the FDCA.
  4. The FDA permits personal importation from any country as long as the individual pays applicable customs duties.
Explanation: The FDA's enforcement discretion does not constitute legal authorization; it is a policy of generally not prosecuting small-quantity personal use importation under specific conditions. A correctly identifies the discretion-versus-authorization distinction. B is incorrect because no formal FDA authorization of 90-day personal importation from Canada exists; this has been proposed but not enacted. C is incorrect because the FDCA does not exempt personal use from its importation provisions. D is incorrect because customs duties are a separate matter and paying them does not resolve the FDCA importation prohibition.

Question 13

Under the FDCA, what is an Import Alert, and what effect does it have on importation?

  1. An Import Alert notifies importers that they must pay additional inspection fees.
  2. An Import Alert allows FDA to detain products at the border without physical examination. (correct answer)
  3. An Import Alert is a notification from a foreign government that a product may be counterfeit.
  4. An Import Alert automatically destroys the detained products without FDA review.
Explanation: An Import Alert is an FDA notice identifying known or suspected violators, allowing products from those sources to be detained without physical examination at the port of entry. B correctly describes the nature and effect of Import Alerts. A is incorrect because Import Alerts do not create fee obligations; they create detention authority. C is incorrect because Import Alerts are FDA documents, not foreign government notifications. D is incorrect because detained products are held pending FDA review and may be exported, reconditioned, or destroyed, but not automatically destroyed.

Question 14

Under the FDCA, what is the general rule regarding the importation of prescription drug products into the United States?

  1. Importation of prescription drugs is freely permitted from any country with equivalent drug safety standards.
  2. Importation of unapproved prescription drugs is generally prohibited, even if approved in other countries, under the FDCA. (correct answer)
  3. Importation is freely permitted from Canada because Canadian drug safety standards are equivalent to those of the United States.
  4. Importation is permitted from any country if the importing individual has a valid U.S. prescription for the drug.
Explanation: The FDCA generally prohibits importing prescription drug products not approved by the FDA for the U.S. market. This applies to both commercial and personal use importation. B correctly states this general prohibition. A is incorrect because equivalence of foreign standards does not override U.S. import approval requirements. C is incorrect because Canadian drug approval does not substitute for U.S. FDA approval; importation from Canada for individuals is technically prohibited under federal law. D is incorrect because a valid U.S. prescription addresses the prescribing authority but does not resolve the importation prohibition.

Question 15

A state enacts a law authorizing pharmacies in that state to import lower-cost drugs from Canada to reduce prescription drug prices for residents. Under federal law, which of the following applies?

  1. State laws cannot authorize activities prohibited by federal law; federal FDCA importation requirements preempt state importation authorization; pharmacies acting under the state law may still face federal liability under the FDCA. (correct answer)
  2. The state law is valid and pharmacies may lawfully import from Canada under it because states have authority over pharmacy practice.
  3. The state law is valid because importation from Canada falls within state police powers.
  4. The state law is valid because the FDA has no jurisdiction over imports from friendly countries.
Explanation: Under the Supremacy Clause, federal law preempts conflicting state law. A state law purporting to authorize drug importation prohibited by the FDCA does not shield pharmacies from federal liability. B correctly identifies the federal preemption analysis. A is incorrect because state police powers over pharmacy practice do not override federal importation law. C is incorrect because state police powers are limited by federal supremacy. D is incorrect because the FDA has jurisdiction over imports regardless of bilateral relationships with foreign countries.

Question 16

Under the FDCA, a manufacturer whose drug products are imported from abroad must meet which of the following requirements regarding GMP compliance?

  1. Foreign manufacturers meet GMP requirements automatically if they hold ISO certification.
  2. Foreign manufacturers are subject to their home country's GMP standards, not U.S. standards.
  3. Foreign manufacturers must comply with U.S. GMP standards, and FDA can inspect and refuse products not meeting these standards. (correct answer)
  4. GMP requirements do not apply to foreign manufacturers because the FDA has no jurisdiction outside the United States.
Explanation: Foreign manufacturers supplying the U.S. market must meet the same GMP standards as domestic manufacturers. The FDA has authority to inspect foreign facilities and may refuse admission of products from non-compliant facilities. A correctly identifies this standard. B is incorrect because ISO certification does not satisfy FDA GMP requirements. C is incorrect because products entering the U.S. must meet U.S. standards regardless of where they were manufactured. D is incorrect because while FDA jurisdiction is limited outside U.S. borders, products offered for import that were manufactured in non-GMP conditions may be refused admission.

Question 17

Under what circumstances may the FDA authorize importation of a drug product that is not FDA-approved, under its 'foreign supply' or 'personal use' import authority?

  1. Whenever a U.S. prescriber writes a prescription for the foreign product.
  2. Whenever a foreign government certifies the product is safe.
  3. Whenever the patient can demonstrate financial hardship in accessing the domestic product.
  4. For personal use when no FDA-approved alternative is available and treatment began abroad. (correct answer)
Explanation: FDA's enforcement discretion for personal importation of unapproved drugs is based on a set of informal criteria: personal use, limited quantity, no unreasonable risk, continuation of foreign treatment, and not substituting for available domestic options. D correctly identifies these criteria. A is incorrect because a U.S. prescription alone does not satisfy FDA personal importation criteria. B is incorrect because foreign government certification is not an FDA personal importation standard. C is incorrect because financial hardship is not one of the FDA's personal importation discretion criteria.

Question 18

Under FDA import regulations, which of the following entities must be registered with the FDA before importing or offering drugs for importation into the United States?

  1. Only the final U.S. importer; foreign manufacturers need not register.
  2. Only the foreign manufacturer; U.S. importers need not register.
  3. Neither foreign manufacturers nor U.S. importers; registration is voluntary.
  4. Foreign manufacturers must register with the FDA before importing drugs. (correct answer)
Explanation: FDCA Section 510 requires foreign drug establishment registration for any manufacturer, repacker, or relabeler supplying drugs to the U.S. market. Unregistered facilities' products may be refused at the border. D correctly identifies this requirement. A is incorrect because the foreign manufacturer must also register. B is incorrect because both parties have registration obligations. C is incorrect because registration is mandatory, not voluntary, for foreign establishments supplying the U.S.

Question 19

The FDA Modernization Act of 1997 included provisions related to reimportation of U.S.-manufactured drugs. Which of the following best describes the reimportation framework?

  1. The 1997 Act authorized unrestricted reimportation of all U.S.-manufactured drugs from any country.
  2. The 1997 Act authorized reimportation of U.S.-manufactured drugs only by veterinarians for animal use.
  3. The 1997 Act allowed conditional reimportation of drugs from Canada, pending HHS Secretary's safety certification. (correct answer)
  4. The 1997 Act prohibited all forms of drug reimportation from any country permanently.
Explanation: The FDA Modernization Act created a conditional reimportation framework requiring HHS Secretary certification of safety -- a certification no Secretary has made, leaving the provision unimplemented. C correctly describes this framework and its non-implementation. A is incorrect because the Act did not authorize unrestricted reimportation. B is incorrect because the provision was not limited to veterinary use. D is incorrect because the Act did not create a permanent prohibition; it created a conditional authorization.

Question 20

Under FDCA Section 801, which of the following products is automatically deemed adulterated or misbranded and may be refused entry into the United States?

  1. Only drugs that contain controlled substances.
  2. Any drug, device, or food appearing to violate FDCA standards. (correct answer)
  3. Only products from countries without a bilateral trade agreement with the United States.
  4. Only products that are on the FDA import alert list.
Explanation: FDCA Section 801 authorizes FDA to refuse admission to any drug that appears to violate the FDCA, including products without U.S. approval, products from non-GMP facilities, and mislabeled products. B correctly describes this broad authority. A is incorrect because the refusal authority extends beyond controlled substances to all FDCA-regulated products. C is incorrect because the refusal authority does not depend on trade agreement status. D is incorrect because while import alerts expedite refusal for known problematic sources, Section 801 authority is not limited to import alert listed products.